Trevi Therapeutics, Inc. (TRVI) Financials

TRVI Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 179.6 million 7.5 million
Dec. 31, 2025 193.4 million 10.2 million
Sept. 30, 2025 199.4 million 9.6 million
June 30, 2025 208.3 million 9.8 million

TRVI Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -16.8 million 2.2 million
Dec. 31, 2025 5.8 million 1.4 million
Sept. 30, 2025 -10.9 million 1.2 million
June 30, 2025 -10.1 million 1.4 million

TRVI Net Income

No data available :(

TRVI Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 171.8 million 364000 -
Dec. 31, 2025 188.3 million - 446000
Sept. 30, 2025 194.9 million - 823000
June 30, 2025 203.9 million - 891000

TRVI Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 145.6 million
Dec. 31, 2025 145.5 million
Sept. 30, 2025 145.1 million
June 30, 2025 130.4 million

TRVI Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 102000 9.9 million 5.0 million -
Dec. 31, 2025 13.5 million 6.2 million 4.0 million -
Sept. 30, 2025 12000 10.1 million 3.8 million -
June 30, 2025 - 9.4 million 4.3 million -

TRVI Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 34000
Dec. 31, 2025 - 31000
Sept. 30, 2025 - -
June 30, 2025 - 38000

TRVI

Price: $14.66

52 week price:
5.41
16.12

Earnings Per Share: -0.32 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 28000

Market Capitalization: 1.9 billion

Links: